Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program
- None.
- None.
Insights
The introduction of the Senhance® Surgical System into Nagoya University Hospital's Pediatric Surgery Department represents a notable advancement in the field of minimally invasive surgery (MIS) for children. The deployment of such technology is significant as it underscores the growing trend of digitization and automation in surgical procedures. The system's specialized instrumentation and advanced clinical intelligence, tailored for pediatric care, could potentially lead to improved surgical outcomes, reduced operation times and lower rates of complications, which are critical factors in pediatric surgeries.
From a business perspective, the adoption of this system by a prominent Japanese institution may serve as a catalyst for increased market penetration within Asia, a region with substantial growth potential for medical devices. As pediatric MIS is a highly specialized field, the successful implementation and reported benefits in a respected hospital like Nagoya University could enhance Asensus Surgical's reputation and drive demand for their systems in other pediatric centers, ultimately impacting the company's revenue stream and market share.
Introducing advanced surgical systems like the Senhance® into pediatric surgery departments can have significant economic implications. The upfront costs associated with leasing such high-tech equipment can be offset by the long-term savings from reduced surgical complications, shorter hospital stays and quicker patient recovery times. Moreover, reusable 3mm instruments not only align with the delicate nature of pediatric surgery but also offer cost-effectiveness over time, compared to disposable instruments. This economic value proposition could encourage other hospitals to consider similar investments, particularly if the technology leads to a competitive advantage in attracting patients seeking high-quality pediatric care.
However, it is important to monitor the actual cost-benefit ratio as the technology is adopted more widely. Factors such as training costs for surgeons, maintenance expenses and potential challenges in integrating such advanced systems into existing hospital workflows must be considered when evaluating the overall economic impact on the healthcare system and the company's profitability.
The strategic move by Asensus Surgical to expand its footprint in the Japanese market with the Senhance® Surgical System may reflect broader trends within the global surgical devices market. The focus on pediatric applications could position the company favorably in a niche yet growing segment. By analyzing market data, one could infer that the success of this installation may influence similar adoptions in other regions, potentially leading to an increase in global sales.
It is also important to consider the competitive landscape. As other companies may develop or introduce similar technologies, Asensus Surgical's early mover advantage and proven track record in pediatric procedures could be pivotal. Continuous innovation and positive clinical outcomes are essential for maintaining this advantage. Market research can provide insights into customer satisfaction and areas for improvement, helping Asensus Surgical to refine its product and marketing strategies accordingly.
The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures
RESEARCH TRIANGLE PARK, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that Nagoya University Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in their Pediatric Surgery Department, at the end of December 2023. This is the first pediatric installation in Japan and the fourth globally for 2023. This Senhance System was previously announced in our January 8, 2024, Corporate Update news release.
"The Senhance System is specifically equipped to meet the demands of pediatric surgery, and we are excited to work with Nagoya University Hospital," noted Anthony Fernando, President and CEO of Asensus Surgical. "With its specialized instrumentation and advanced clinical intelligence, the system offers a unique advantage for pediatric patients, reducing invasiveness and increasing precision in a way that sets it apart. Our experience in Europe and the United States has shown success in various pediatric procedures, and we're eager to extend these benefits in Japan."
Nagoya University Hospital, Japan, initiated a Senhance® Surgical System dedicated to pediatric procedures
"The Senhance System provides a valuable solution for pediatric surgery," stated Dr. Hiroo Uchida of the Department of Pediatric Surgery at Nagoya University Hospital. "Designed with smaller patients in mind, the reusable 3mm instruments offer a distinct advantage. Having our experience in laparoscopic surgery, we find the system very adaptable, such as instinctive camera control and haptic feedback with crucial safety features. In addition, we believe the system offers economic value. This represents a significant step forward aligning with our goal of providing the best care for our young patients."
About Nagoya University Hospital
Established in 1871, Nagoya University Hospital is one of Japan’s leading medical institutions, with 35 departments and 32 central medical facilities, and accepts about 500,000 outpatients annually. In 2019, it became the first national university hospital to obtain certification from the Joint Commission International (JCI), and it was renewed in March 2022, when it was re-examined. The hospital's management ethos centers on leveraging leading-edge technologies to provide the best possible healthcare services.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit™ to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, and digital laparoscopy with the Senhance Surgical System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc/
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok:https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and Nagoya University Hospital in Japan initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance System’s success in pediatric patients in Europe and the United States will extend to Japan and whether the Senhance System will help Nagoya University Hospital achieve its goal of providing the best care for young patients. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/41ac9c05-4dfb-4a31-ac83-122e37b9b24f
FAQ
What is the ticker symbol for Asensus Surgical, Inc.?
Which hospital initiated a Senhance Surgical System dedicated to pediatric procedures?
How many pediatric installations of the Senhance Surgical System were there globally in 2023?
What advantages does the Senhance System offer for pediatric surgery?
Who is the President and CEO of Asensus Surgical?
